RESUMEN
BACKGROUND: Neuropathic pain represents a therapeutic challenge, and treatments with increased efficacy and tolerability still need to be developed. Opiorphin protects endogenous enkephalins from degradation, potentiating enkephalin-dependent analgesia via the activation of opioid pathways. Enkephalins are natural ligands of opioid receptors, with strong affinity for δ-opioid receptors. Expression of functional δ-opioid receptors increases in sensory neurons after peripheral nerve injury in neuropathic pain models. In a postoperative pain model, opiorphin and its stable analog STR-324 have an analgesic potency comparable to that of morphine, but without adverse opioid-related side effects. Consequently, administration of endogenous opiorphin peptides or STR-324 might be effective in managing peripheral neuropathic pain. METHODS: In this study, STR-324 was administered intravenously over the course of 7 days to rats with mononeuropathy induced by L5-L6 spinal nerve root ligation. The rats exhibited mechanical allodynia, thermal hyperalgesia, and spontaneous pain-related behavior throughout the testing period. RESULTS: Here, we report that the continuous administration of STR-324 significantly reduced mechanical allodynia and spontaneous pain-related behavior from day 2 to day 7 in animals that received 10 or 50 µg/h of STR-324 as compared to placebo-treated animals (P < .00001 and P < .0011, respectively, for mechanical allodynia; P = .028 and P = .0049, respectively, for spontaneous pain-related behavior). In addition, STR-324 reduced the pain-evoked expression of spinal c-Fos in this model, demonstrating that it acts at least in part through inhibition of endogenous nociceptive pathways. CONCLUSIONS: These observations suggested that STR-324 may be an effective addition to the multimodal approach for treating clinical neuropathic pain.
Asunto(s)
Modelos Animales de Enfermedad , Hiperalgesia/tratamiento farmacológico , Neuralgia/tratamiento farmacológico , Oligopéptidos/administración & dosificación , Dimensión del Dolor/efectos de los fármacos , Proteínas y Péptidos Salivales/administración & dosificación , Administración Intravenosa , Animales , Hiperalgesia/metabolismo , Hiperalgesia/patología , Masculino , Neuralgia/metabolismo , Neuralgia/patología , Oligopéptidos/química , Dimensión del Dolor/métodos , Ratas , Ratas Sprague-Dawley , Proteínas y Péptidos Salivales/químicaRESUMEN
OBJECTIVES: Idiopathic Burning mouth syndrome (iBMS) is a poorly understood affection characterized by persistent pain in the oral cavity without any clinical or biological abnormality. Opiorphin is a natural inhibitor of enkephalin-inactivating ectopeptidases, mainly produced by salivary glands, that has demonstrated analgesic properties. The objective of the present case-control study was to test the hypothesis of a decrease in opiorphin levels in iBMS patients. MATERIALS AND METHODS: Twenty-one iBMS patients and 21 matched controls subjects were included between 2011 and 2013. Submandibular and sublingual salivary, blood, and urinary opiorphin levels of iBMS patients were compared to controls. RESULTS: Results are expressed as mean values ± SD and compared using the Wilcoxon Signed Rank test. Correlations were analyzed with Spearman coefficient. The level of significance was fixed at p < 0.05. Opiorphin levels in iBMS and controls were respectively (in ng/ml) in basal saliva: 37.8 ± 42.5 and 67.6 ± 188.9 (p = NS); stimulated saliva: 28.8 ± 25.3 and 31.1 ± 29.1 (p = NS); blood: 4.6 ± 5.4 and 1.9 ± 1.4 (p < 0.05); and urines: 68.5 ± 259.8 and 8.9 ± 6.2 (p = NS). CLINICAL RELEVANCE: In conclusion, the lack of significative difference in salivary opiorphin levels between iBMS and controls does not favor a direct local role for opiorphin in the etiopathogeny of iBMS. However, higher blood opiorphin levels may reflect a systemic dysregulation in iBMS. Trial registration NCT02686359 https://clinicaltrials.gov/ct2/show/NCT02686359.
Asunto(s)
Síndrome de Boca Ardiente/metabolismo , Oligopéptidos/metabolismo , Proteínas y Péptidos Salivales/metabolismo , Biomarcadores/metabolismo , Síndrome de Boca Ardiente/psicología , Estudios de Casos y Controles , Cromatografía Líquida de Alta Presión , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Masculino , Persona de Mediana Edad , Dimensión del DolorRESUMEN
BACKGROUND: Opiorphin is a naturally occurring potent analgesic human peptide. It protects enkephalins from degradation and inhibits pain perception in various acute pain models via activation of endogenous opioid pathways. However, the efficacy of opiorphin continuous infusion and its chemically stable form, STR-324, in postoperative pain is unknown. METHODS: Using the Brennan model of plantar incision-induced hypersensitivity, the authors examined the postsurgical analgesic response to mechanical and thermal stimuli of 7-day continuously intravenously infused drugs (8 to 10 rats per group). Antinociception from opiorphin with reference to morphine and STR-324 was assessed. Spinal c-Fos expression and the involvement of opioid receptor-dependent pathways were investigated. The occurrence of respiratory and hemodynamic adverse effects of opiorphin was also tested. RESULTS: Intravenous infusion of opiorphin significantly reduced responses to mechanical stimuli from days 1 to 4 post surgical period at 143 to 175-kPa mean ranges compared with 23 to 30-kPa mean ranges for vehicle (P < 0.05). During the 3-day postoperative period, no respiratory rate, oxygen saturation, arterial pressure, or heart rate adverse effects were induced by opiorphin. STR-324 consistently inhibited mechanical and thermal hyperalgesia with similar potency as that of opiorphin. Mechanistic analyses demonstrated that the STR-324 antinociceptive effect was reversed by the opioid antagonist, naloxone. Also, STR-324 significantly reduced the number of pain-evoked spinal cFos-immunoreactive nuclei. CONCLUSION: Intravenous infusion of opiorphin and STR-324 produced significant antinociceptive effect in a postoperative pain model. This study demonstrates that STR-324 is effective in postoperative pain management due to its strong antihyperalgesic effects mediated via opioid-dependent antinociceptive pathways. Opiorphin analog should represent a new class of potent and safe analgesics.
Asunto(s)
Analgesia/métodos , Analgésicos/farmacología , Oligopéptidos/farmacología , Dolor Postoperatorio/tratamiento farmacológico , Receptores Opioides/efectos de los fármacos , Proteínas y Péptidos Salivales/farmacología , Animales , Masculino , Ratas , Ratas Sprague-DawleyRESUMEN
The synthesis of bioinspired unnatural backbones leading to foldamers can provide effective peptide mimics with improved properties in a physiological environment. This approach has been applied to the design of structural mimics of membrane active antimicrobial peptides (AMPs) for which activities in vitro have been reported. Yet activities and pharmacokinetic properties in vivo in animal models have remained largely unexplored. Here, we report helical oligourea AMP mimics that are active in vitro against bacterial forms of Bacillus anthracis encountered in vivo, as well as in vivo in inhalational and cutaneous mouse models of B. anthracis infection. The pharmacokinetic profile and the tissue distribution were investigated by ß-radio imager whole-body mapping in mice. Low excretion and recovery of the native oligourea in the kidney following intravenous injection is consistent with high stability in vivo. Overall these results provide useful information that support future biomedical development of urea-based foldamer peptide mimics.
Asunto(s)
Carbunco/tratamiento farmacológico , Antibacterianos/uso terapéutico , Péptidos Catiónicos Antimicrobianos/uso terapéutico , Bacillus anthracis/efectos de los fármacos , Peptidomiméticos/uso terapéutico , Urea/uso terapéutico , Animales , Antibacterianos/química , Antibacterianos/farmacocinética , Antibacterianos/farmacología , Péptidos Catiónicos Antimicrobianos/química , Péptidos Catiónicos Antimicrobianos/farmacocinética , Péptidos Catiónicos Antimicrobianos/farmacología , Femenino , Ratones , Ratones Endogámicos BALB C , Modelos Moleculares , Peptidomiméticos/química , Peptidomiméticos/farmacocinética , Peptidomiméticos/farmacología , Urea/análogos & derivados , Urea/farmacocinética , Urea/farmacologíaRESUMEN
The dual inhibitory action of the pain related peptide opiorphin (H-Gln-Arg-Phe-Ser-Arg-OH) against neutral endopeptidase (NEP) and aminopeptidase N (AP-N) was further investigated by a SAR study involving minor modifications on the polar side chains of Arg residues and glycosylation with monosaccharides at Ser. None of them exerted dual or individual inhibitory potency superior than opiorphin. However, the correlations deduced offer further proof for the key role of these residues upon the binding and bioactive conformational stabilization of opiorphin. NMR conformational studies on the glycopeptides suggest that they are still very flexible compounds that may attain their respective bioactive conformations.
Asunto(s)
Antígenos CD13/antagonistas & inhibidores , Neprilisina/antagonistas & inhibidores , Oligopéptidos/química , Proteínas y Péptidos Salivales/química , Acetilgalactosamina/química , Acetilglucosamina/química , Sustitución de Aminoácidos , Arginina/química , Glicopéptidos/química , Humanos , Modelos Moleculares , Estructura Terciaria de Proteína , Serina/química , Relación Estructura-ActividadRESUMEN
Endogenously occurring opioid peptides are rapidly metabolized by different ectopeptidases. Human opiorphin is a recently discovered natural inhibitor of the enkephalin-inactivating neutral endopeptidase (NEP) and aminopeptidase-N (AP-N) (Wisner et al., 2006). To date, in vitro receptor binding experiments must be performed either in the presence of a mixture of peptidase inhibitors and/or at low temperatures, to block peptidase activity. Here we demonstrate that, compared to classic inhibitor cocktails, opiorphin dramatically increases the binding of [(3)H]MERF and [(3)H]MEGY ligands to rat brain membrane preparations. We found that at 0 °C the increase in specific binding is as high as 40-60% and at 24 °C this rise was even higher. In contrast, the binding of the control [(3)H]endomorphin-1, which is relatively slowly degraded in rat brain membrane preparations, was not enhanced by opiorphin compared to other inhibitors. In addition, in homologous binding displacement experiments, the IC(50) affinity values measured at 24 °C were also significantly improved using opiorphin compared to the inhibitor cocktail. In heterologous binding experiments the differences were less obvious, but still pronounced using [(3)H]MERF and MEGY compared to dynorphin(1-11), or naloxone and DAGO competitor ligands.
Asunto(s)
Encéfalo/metabolismo , Encefalina Metionina/análogos & derivados , Oligopéptidos/farmacología , Inhibidores de Proteasas/farmacología , Receptores Opioides/metabolismo , Proteínas y Péptidos Salivales/farmacología , Animales , Unión Competitiva , Membrana Celular/efectos de los fármacos , Membrana Celular/metabolismo , Encefalina Metionina/metabolismo , Masculino , Oligopéptidos/fisiología , Unión Proteica , Ratas , Ratas Endogámicas , Ratas Wistar , Proteínas y Péptidos Salivales/fisiologíaRESUMEN
Toward developing new potential analgesics, this first structure-activity relationship study of opiorphin (H-Gln-Arg-Phe-Ser-Arg-OH), a human peptide inhibiting enkephalin degradation, was performed. A systematic Ala scanning proved that Phe(3) is a key residue for neprilysin and aminopeptidase N (AP-N) ectoenkephalinase inhibition. A series of Phe(3)-halogenated analogues revealed that halogen bonding based optimization strategies are not applicable to this residue. Additional substituted Phe(3) derivatives showed that replacing l-Phe(3) for d-Phe(3) increased the AP-N inhibition potency by 1 order of magnitude. NMR studies and molecular mechanics calculations indicated that the improved potency may be due to CH-π stacking interactions between the aromatic ring of d-Phe(3) and the Hγ protons of Arg(2). This structural motif is not possible for the native opiorphin and may be useful for the design of further potent and metabolically stable analogues.
Asunto(s)
Analgésicos/síntesis química , Antígenos CD13/antagonistas & inhibidores , Neprilisina/antagonistas & inhibidores , Oligopéptidos/síntesis química , Inhibidores de Proteasas/síntesis química , Proteínas y Péptidos Salivales/síntesis química , Analgésicos/química , Antígenos CD13/química , Pruebas de Enzimas , Humanos , Espectroscopía de Resonancia Magnética , Modelos Moleculares , Neprilisina/química , Oligopéptidos/química , Inhibidores de Proteasas/química , Teoría Cuántica , Proteínas y Péptidos Salivales/química , Técnicas de Síntesis en Fase Sólida , Soluciones , Relación Estructura-ActividadRESUMEN
The conformational profiles for the endogenous peptide Opiorphin and a set of seven analogues exhibiting different inhibitory activities toward human aminopeptidase N (hAPN) and human neprilysin (hNEP) were independently computed to deduce a bioactive conformation that Opiorphin may adopt when binding these two enzymes. The conformational space was thoroughly sampled using an iterative simulated annealing protocol, and a library of low-energy conformers was generated for each peptide. Bioactive Opiorphin conformations fitting our experimental structure-activity relationship data were identified for hAPN and hNEP using computational pairwise comparisons between each of the unique low-energy conformations of Opiorphin and its analogues. The obtained results provide a structural explanation for the dual hAPN and hNEP inhibitory activity of Opiorphin and show that the inborn flexibility of Opiorphin is essential for its analgesic activity.
RESUMEN
Animal models of anxious disorders found in humans, such as panic disorder and posttraumatic stress disorder, usually include spontaneous and conditioned fear that triggers escape and avoidance behaviors. The development of a panic disorder model with a learned component should increase knowledge of mechanisms involved in anxiety disorders. In our ethological model of extreme anxiety in the rat, forced apnea was combined with cold water vaporization in an inescapable situation. Based on the reactions of vehicle controls, behaviors involved in paroxysmic fear were passive (freezing) and active (jumping) reactions. Our results show that subchronic fluoxetine (5 mg/kg, IP, 21 days) and imipramine (10 mg/kg, IP, 14 days) administration alleviated freezing and jumping behaviors, whereas acute fluoxetine (1 mg/kg, IP) provoked opposite effects. Acute low dose of diazepam (1 mg/kg, IP) was not effective, whereas the higher dose of 3 mg/kg, IP, and clonazepam (1 mg/kg, IP) only had an effect on jumping. Paroxysmic fear generated in this experimental condition may therefore mimic the symptomatology observed in patients with anxiety disorders.
RESUMEN
Diabetes results in a myriad of vascular complications, often referred to as diabetic vasculopathy, which encompasses both microvascular [erectile dysfunction (ED), retinopathy, neuropathy, and nephropathy] and macrovascular complications (hypertension, coronary heart disease, and myocardial infarction). In diabetic animals and patients with ED, there is decreased opiorphin or opiorphin-related gene expression in corporal tissue. Both opiorphin and the rat homologous peptide sialorphin are found circulating in the plasma. In the present study, we investigated if diabetes induced changes in plasma sialorphin levels and if changes in these levels could modulate the biochemistry and physiology of vascular smooth muscle. We show that circulating sialorphin levels are reduced in a rat model of type I diabetes. Intracorporal injection of plasmids expressing sialorphin into diabetic rats restores sialorphin levels to those seen in the blood of nondiabetic animals and results in both improved erectile function and blood pressure. Sialorphin modulated the ability of C-type natriuretic peptide to relax both corporal and aortic smooth muscle strips and of bradykinin to regulate intracellular calcium levels in both corporal and aortic smooth muscle cells. We have previously shown that expression of genes encoding opiorphins is increased when erectile function is improved. Our findings thus suggest that by affecting circulating levels of opiorphin-related peptides, proper erectile function is not only an indicator but also a modulator of overall vascular health of a man.
Asunto(s)
Diabetes Mellitus Tipo 2/tratamiento farmacológico , Angiopatías Diabéticas/tratamiento farmacológico , Oligopéptidos/farmacología , Proteínas y Péptidos Salivales/farmacología , Animales , Aorta Torácica/citología , Aorta Torácica/efectos de los fármacos , Presión Sanguínea/genética , Presión Sanguínea/fisiología , Bradiquinina/farmacología , Calcio/metabolismo , Señalización del Calcio/genética , Señalización del Calcio/fisiología , Diabetes Mellitus Experimental/tratamiento farmacológico , Diabetes Mellitus Experimental/fisiopatología , Diabetes Mellitus Tipo 2/patología , Angiopatías Diabéticas/patología , Técnicas de Transferencia de Gen , Técnicas In Vitro , Músculo Liso Vascular/efectos de los fármacos , Músculo Liso Vascular/fisiología , Péptido Natriurético Tipo-C/metabolismo , Erección Peniana/efectos de los fármacos , Erección Peniana/fisiología , Fragmentos de Péptidos/farmacología , Ratas , Ratas Endogámicas F344 , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
The terminal homologation by CH(2) insertion into the peptides mentioned in the title is described. This involves replacement of the N-terminal amino acid residue by a ß(2) - and of the C-terminal amino acid residue by a ß(3) -homo-amino acid moiety (ß(2) hXaa and ß(3) hXaa, resp.; Fig.â 1). In this way, the structure of the peptide chain from the N-terminal to the C-terminal stereogenic center is identical, and the modified peptide is protected against cleavage by exopeptidases (Figs.â 2 and 3). Neurotensin (NT; 1) and its C-terminal fragment NT(8-13) are ligands of the G-protein-coupled receptors (GPCR) NT1, NT2, NT3, and NT analogs are promising tools to be used in cancer diagnostics and therapy. The affinities of homologated NT analogs, 2b-2e, for NT1 and NT2 receptors were determined by using cell homogenates and tumor tissues (Tableâ 1); in the latter experiments, the affinities for the NT1 receptor are more or less the same as those of NT (0.5-1.3 vs. 0.6â nM). At the same time, one of the homologated NT analogs, 2c, survives in human plasma for 7 days at 37° (Fig.â 6). An NMR analysis of NT(8-13) (Tablesâ 2 and 4, and Fig.â 8) reveals that this N-terminal NT fragment folds to a turn in CD(3) OH. - In the case of the human analgesic opiorphin (3a), a pentapeptide, and of the HIV-derived B27-KK10 (4a), a decapeptide, terminal homologation (â3b and 4b, resp.) led to a 7- and 70-fold half-life increase in plasma (Fig.â 9). With N-terminally homologated NPY, 5c, we were not able to determine serum stability; the peptide consisting of 36 amino acid residues is subject to cleavage by endopetidases. Three of the homologated compounds, 2b, 2c, and 5c, were shown to be agonists (Fig.â 7 and 11). A comparison of terminal homologation with other stability-increasing terminal modifications of peptides is performed (Fig.â 5), and possible applications of the neurotensin analogs, described herein, are discussed.
Asunto(s)
VIH/química , Neuropéptido Y/química , Neurotensina/análogos & derivados , Oligopéptidos/química , Proteínas y Péptidos Salivales/química , Suero/metabolismo , Proteínas Virales/química , Secuencia de Aminoácidos , Materiales Biomiméticos/química , Materiales Biomiméticos/metabolismo , Línea Celular , Línea Celular Tumoral , Exopeptidasas/metabolismo , VIH/metabolismo , Humanos , Datos de Secuencia Molecular , Neuropéptido Y/metabolismo , Neurotensina/metabolismo , Oligopéptidos/metabolismo , Unión Proteica , Estabilidad Proteica , Receptores de Neurotensina/metabolismo , Proteínas y Péptidos Salivales/metabolismo , Proteínas Virales/metabolismoRESUMEN
In a previous clinical study, a probiotic formulation (PF) consisting of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 (PF) decreased stress-induced gastrointestinal discomfort. Emerging evidence of a role for gut microbiota on central nervous system functions therefore suggests that oral intake of probiotics may have beneficial consequences on mood and psychological distress. The aim of the present study was to investigate the anxiolytic-like activity of PF in rats, and its possible effects on anxiety, depression, stress and coping strategies in healthy human volunteers. In the preclinical study, rats were daily administered PF for 2 weeks and subsequently tested in the conditioned defensive burying test, a screening model for anti-anxiety agents. In the clinical trial, volunteers participated in a double-blind, placebo-controlled, randomised parallel group study with PF administered for 30 d and assessed with the Hopkins Symptom Checklist (HSCL-90), the Hospital Anxiety and Depression Scale (HADS), the Perceived Stress Scale, the Coping Checklist (CCL) and 24 h urinary free cortisol (UFC). Daily subchronic administration of PF significantly reduced anxiety-like behaviour in rats (P < 0·05) and alleviated psychological distress in volunteers, as measured particularly by the HSCL-90 scale (global severity index, P < 0·05; somatisation, P < 0·05; depression, P < 0·05; and anger-hostility, P < 0·05), the HADS (HADS global score, P < 0·05; and HADS-anxiety, P < 0·06), and by the CCL (problem solving, P < 0·05) and the UFC level (P < 0·05). L. helveticus R0052 and B. longum R0175 taken in combination display anxiolytic-like activity in rats and beneficial psychological effects in healthy human volunteers.
Asunto(s)
Adaptación Psicológica/efectos de los fármacos , Ansiedad/tratamiento farmacológico , Bifidobacterium , Lactobacillus helveticus , Probióticos/uso terapéutico , Psicotrópicos/uso terapéutico , Estrés Psicológico/tratamiento farmacológico , Adulto , Ira/efectos de los fármacos , Animales , Ansiolíticos/farmacología , Ansiolíticos/uso terapéutico , Depresión/tratamiento farmacológico , Método Doble Ciego , Femenino , Hostilidad , Humanos , Masculino , Persona de Mediana Edad , Probióticos/farmacología , Psicotrópicos/farmacología , Ratas , Ratas Wistar , Índice de Severidad de la Enfermedad , Trastornos Somatomorfos/tratamiento farmacológicoRESUMEN
OBJECTIVE: To determine if the mature peptide product of the Vcsa1 gene, sialorphin, could restore erectile function in ageing rats, and whether these effects are mediated through relaxation of corporal smooth muscle tissue, as we recently reported that Vcsa1 is one of the most down-regulated genes in the corpora of rats in three distinct models of erectile dysfunction, and gene transfer of plasmids expressing Vcsa1 into the corpora of ageing rats restored erectile function. MATERIALS AND METHODS: Sialorphin was injected intracorporeally into retired breeder rats, and the effect on the physiology of corporal tissue was analysed by intracorporal/blood pressure (ICP/BP) measurement at different times after injection. In organ-bath studies, the ability of sialorphin (1 microg/mL) to enhance C-type natriuretic peptide (CNP) relaxation of corporal smooth muscle tissue strips was investigated after pre-contraction with 1 microm phenylephrine. RESULTS: Intracorporal injection of 100 microg sialorphin into retired breeder rats resulted in a time-dependent increase in the ICP/BP response to electrostimulation of the cavernosal nerve. After 55-65 min the ICP/BP ratio increased to approximately 0.6, a value associated with normal erectile function. In organ-bath studies after pre-contraction with 1 microm phenylephrine, 1 microm CNP significantly (67%) increased the relaxation rate of corporal tissue. This rate of relaxation was increased by 2.5-fold after incubation with sialorphin (1 microg/mL) compared with carrier alone. CONCLUSION: These results show that sialorphin has a role in erectile function, probably through a mechanism that involves relaxation of corporal smooth muscle tissue.
Asunto(s)
Relajación Muscular/efectos de los fármacos , Músculo Liso/efectos de los fármacos , Fármacos Neuromusculares/farmacología , Erección Peniana/efectos de los fármacos , Precursores de Proteínas/farmacología , Proteínas y Péptidos Salivales/farmacología , Envejecimiento/fisiología , Animales , Masculino , Ratas , Ratas Sprague-DawleyRESUMEN
Mammalian zinc ectopeptidases play important roles in turning off neural and hormonal peptide signals at the cell surface, notably those processing sensory information. We report here the discovery of a previously uncharacterized physiological inhibitor of enkephalin-inactivating zinc ectopeptidases in humans, which we have named Opiorphin. It is a QRFSR peptide that inhibits two enkephalin-catabolizing ectoenzymes, human neutral ecto-endopeptidase, hNEP (EC 3.4.24.11), and human ecto-aminopeptidase, hAP-N (EC 3.4.11.2). Opiorphin displays potent analgesic activity in chemical and mechanical pain models by activating endogenous opioid-dependent transmission. Its function is closely related to the rat sialorphin peptide, which is an inhibitor of pain perception and acts by potentiating endogenous mu- and delta-opioid receptor-dependent enkephalinergic pathways. Here we demonstrate the functional specificity in vivo of human Opiorphin. The pain-suppressive potency of Opiorphin is as effective as morphine in the behavioral rat model of acute mechanical pain, the pin-pain test. Thus, our discovery of Opiorphin is extremely exciting from a physiological point of view in the context of endogenous opioidergic pathways, notably in modulating mood-related states and pain sensation. Furthermore, because of its in vivo properties, Opiorphin may have therapeutic implications.
Asunto(s)
Analgésicos/metabolismo , Antígenos CD13 , Neprilisina , Oligopéptidos/metabolismo , Péptidos Opioides/metabolismo , Proteínas y Péptidos Salivales/metabolismo , Adenosina Desaminasa/genética , Adenosina Desaminasa/metabolismo , Secuencia de Aminoácidos , Animales , Conducta Animal/fisiología , Antígenos CD13/antagonistas & inhibidores , Antígenos CD13/genética , Antígenos CD13/metabolismo , Línea Celular , Dipeptidil Peptidasa 4/genética , Dipeptidil Peptidasa 4/metabolismo , Encefalinas/metabolismo , Glicoproteínas/genética , Glicoproteínas/metabolismo , Humanos , Masculino , Neprilisina/antagonistas & inhibidores , Neprilisina/genética , Neprilisina/metabolismo , Oligopéptidos/genética , Péptidos Opioides/genética , Dimensión del Dolor , Ratas , Ratas Wistar , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Saliva/química , Proteínas y Péptidos Salivales/genéticaRESUMEN
Excitotoxic damage appears to be a critical factor in the formation of perinatal brain lesions associated with cerebral palsy (CP). When injected into newborn mice, the glutamatergic analogue, ibotenate, produces cortical lesions and white matter cysts that mimic human perinatal brain lesions. Neuropeptides are neuronal activity modulators and could therefore modulate glutamate-induced lesions. However, neuropeptides are rapidly degraded by peptidases. Racecadotril, which is rapidly metabolized to its active metabolite thiorphan, is a neutral endopeptidase (NEP) inhibitor used in clinical practice for diarrhoea with a remarkable safety profile. This study aimed to test the original hypothesis that thiorphan could be neuroprotective against ibotenate-induced lesions in newborn mice. Intraperitoneal administration of thiorphan reduced ibotenate-induced cortical lesions by up to 57% and cortical caspase-3 cleavage by up to 59%. This neuroprotective effect was long-lasting and was still observed when thiorphan was administered 12 h after the insult, showing a remarkable window for therapeutic intervention. Further supporting the neuroprotective effect of pharmacological blockade of NEP, mouse pups with a genetic deletion of NEP displayed a significantly reduced size of the ibotenate-induced cortical grey matter lesion when compared with wild-type animals. Thiorphan effects were mimicked by substance P (SP) and, in a less potent manner, by neurokinin A. Thiorphan effects were inhibited by blockers of NK1 and NK2 receptors. Real-time reverse transcription-polymerase chain reaction, autoradiography and immunohistochemistry confirmed the expression of NK1 and NK2 receptors in the neonatal murine neocortex. These data demonstrate that thiorphan prevents neonatal excitotoxic cortical damage, an effect largely mediated by SP. Thiorphan could represent a promising drug for the prevention of CP, which remains a challenging disease. In a broader context, these results also raise potential implications for the prevention of neurodegenerative diseases involving glutamate-mediated excitotoxic neuronal death.
Asunto(s)
Corteza Cerebral/efectos de los fármacos , Parálisis Cerebral/patología , Neprilisina/antagonistas & inhibidores , Fármacos Neuroprotectores/administración & dosificación , Inhibidores de Proteasas/administración & dosificación , Tiorfan/administración & dosificación , Animales , Animales Recién Nacidos , Caspasa 3/metabolismo , Muerte Celular/efectos de los fármacos , Células Cultivadas , Corteza Cerebral/patología , Parálisis Cerebral/prevención & control , Agonistas de Aminoácidos Excitadores , Femenino , Ácido Iboténico , Inmunohistoquímica/métodos , Inyecciones Intraperitoneales , Masculino , Ratones , Ratones Endogámicos C57BL , Neuroquinina A/farmacología , Antagonistas del Receptor de Neuroquinina-1 , Neuronas/efectos de los fármacos , Neurotransmisores/farmacología , Receptores de Neuroquinina-2/antagonistas & inhibidores , Convulsiones/prevención & control , Sustancia P/farmacologíaRESUMEN
Sialorphin is an exocrine and endocrine signaling mediator, which has been identified by a genomic approach. It is synthesized predominantly in the submandibular gland and prostate of adult rats in response to androgen steroids and is released locally and systemically in response to stress. We now demonstrate that the cell surface molecule to which sialorphin binds in vivo in the rat kidney is the membrane-anchored neutral endopeptidase (neprilysin; NEP, EC 3.4.24.11). NEP plays an important role in nervous and peripheral tissues, as it turns off several peptide-signaling events at the cell surface. We show that sialorphin prevents spinal and renal NEP from breaking down its two physiologically relevant substrates, substance P and Met-enkephalin in vitro. Sialorphin inhibited the breakdown of substance P with an IC50 of 0.4-1 microM and behaved as a competitive inhibitor. In vivo, i.v. sialorphin elicited potent antinociceptive responses in two behavioral rat models of injury-induced acute and tonic pain, the pin-pain test and formalin test. The analgesia induced by 100-200 mcicrog/kg doses of sialorphin required the activation of mu- and delta-opioid receptors, consistent with the involvement of endogenous opioid receptors in enkephalinergic transmission. We conclude that sialorphin protects endogenous enkephalins released after nociceptive stimuli by inhibiting NEP in vivo. Sialorphin is a natural systemically active regulator of NEP activity. Furthermore, our study provides evidence that it is a physiological modulator of pain perception after injury and might be the progenitor of a new class of therapeutic molecules.
Asunto(s)
Analgésicos/farmacología , Leucina/análogos & derivados , Proteínas de la Membrana/fisiología , Naltrexona/análogos & derivados , Neprilisina/antagonistas & inhibidores , Dolor/tratamiento farmacológico , Inhibidores de Proteasas/farmacología , Precursores de Proteínas/fisiología , Proteínas y Péptidos Salivales/fisiología , Secuencia de Aminoácidos , Analgésicos/uso terapéutico , Animales , Encefalina Metionina/metabolismo , Formaldehído/toxicidad , Glicopéptidos/farmacología , Riñón/efectos de los fármacos , Riñón/enzimología , Leucina/farmacología , Masculino , Proteínas de la Membrana/antagonistas & inhibidores , Datos de Secuencia Molecular , Naltrexona/farmacología , Dolor/inducido químicamente , Dimensión del Dolor , Próstata/metabolismo , Inhibidores de Proteasas/uso terapéutico , Precursores de Proteínas/química , Precursores de Proteínas/farmacología , Precursores de Proteínas/uso terapéutico , Ratas , Ratas Wistar , Receptores Opioides delta/efectos de los fármacos , Receptores Opioides delta/fisiología , Receptores Opioides mu/efectos de los fármacos , Receptores Opioides mu/fisiología , Proteínas y Péptidos Salivales/química , Proteínas y Péptidos Salivales/farmacología , Proteínas y Péptidos Salivales/uso terapéutico , Médula Espinal/efectos de los fármacos , Médula Espinal/enzimología , Glándula Submandibular/metabolismo , Sustancia P/metabolismo , Tiorfan/farmacología , Heridas y Lesiones/fisiopatologíaRESUMEN
Proline racemase catalyzes the interconversion of L- and D-proline enantiomers and has to date been described in only two species. Originally found in the bacterium Clostridium sticklandii, it contains cysteine residues in the active site and does not require co-factors or other known coenzymes. We recently described the first eukaryotic amino acid (proline) racemase, after isolation and cloning of a gene from the pathogenic human parasite Trypanosoma cruzi. Although this enzyme is intracellularly located in replicative non-infective forms of T. cruzi, membrane-bound and secreted forms of the enzyme are present upon differentiation of the parasite into non-dividing infective forms. The secreted form of proline racemase is a potent host B-cell mitogen supporting parasite evasion of specific immune responses. Here we describe that the TcPRAC genes in T. cruzi encode functional intracellular or secreted versions of the enzyme exhibiting distinct kinetic properties that may be relevant for their relative catalytic efficiency. Although the Km of the enzyme isoforms were of a similar order of magnitude (29-75 mM), Vmax varied between 2 x 10(-4 )and 5.3 x 10(-5) mol of L-proline/s/0.125 microM of homodimeric recombinant protein. Studies with the enzyme-specific inhibitor and abrogation of enzymatic activity by site-directed mutagenesis of the active site Cys330 residue reinforced the potential of proline racemase as a critical target for drug development against Chagas' disease. Finally, we propose a protein signature for proline racemases and suggest that the enzyme is present in several other pathogenic and non-pathogenic bacterial genomes of medical and agricultural interest, yet absent in mammalian host, suggesting that inhibition of proline racemases may have therapeutic potential.